May 9 (Reuters) - Johnson & Johnson JNJ.N said on Friday its experimental psoriasis drug met the main goal in a late-stage study on patients 12 years and older.
Disclaimer: The information provided on this website is for educational and informational purposes only and should not be considered financial or investment advice.